# Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

> **NCT03983395** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ichnos Sciences SA** · enrollment: 1 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** ISB 1302 250 ng/kg
- **BIOLOGICAL:** ISB 1302 325 ng/kg
- **BIOLOGICAL:** ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22
- **BIOLOGICAL:** ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22
- **BIOLOGICAL:** ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22
- **BIOLOGICAL:** ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22
- **BIOLOGICAL:** ISB 1302 escalating doses,1200 ng/kg D15,22
- **BIOLOGICAL:** ISB 1302 at the MTD and/or RP2D dose

## Key facts

- **NCT ID:** NCT03983395
- **Lead sponsor:** Ichnos Sciences SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-08
- **Primary completion:** 2020-07-24
- **Final completion:** 2020-07-24
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The study was terminated during Part 1 (dose escalation), and Part 2 (expansion) of the study was not initiated. This study was voluntarily terminated due to a business decision not to proceed with the ISB 1302 asset, and not due to any safety issue.
- **Last updated:** 2021-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03983395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03983395, "Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03983395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*